Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors

U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07857135) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors' on Sept. 20.

Brief Summary: This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.

Study Start Date: Oct. 03

Study Type: INTERVENTIONAL

Condition: Advanced/Metastatic Solid Tumors

Intervention: DRUG: SYS6088

SYS6088, administered per protocol.

DRUG: Regorafenib

Reg...